ATE529744T1 - Prionproteinliganden und verfahren zu ihrer verwendung - Google Patents

Prionproteinliganden und verfahren zu ihrer verwendung

Info

Publication number
ATE529744T1
ATE529744T1 AT03808431T AT03808431T ATE529744T1 AT E529744 T1 ATE529744 T1 AT E529744T1 AT 03808431 T AT03808431 T AT 03808431T AT 03808431 T AT03808431 T AT 03808431T AT E529744 T1 ATE529744 T1 AT E529744T1
Authority
AT
Austria
Prior art keywords
prion protein
ligands
prion
methods
protein ligands
Prior art date
Application number
AT03808431T
Other languages
English (en)
Inventor
David Hammond
Julia Lathrop
Larisa Cervenakova
Ruben Carbonell
Original Assignee
Pathogen Removal & Diagnostic Technologies Inc
Univ North Carolina State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pathogen Removal & Diagnostic Technologies Inc, Univ North Carolina State filed Critical Pathogen Removal & Diagnostic Technologies Inc
Application granted granted Critical
Publication of ATE529744T1 publication Critical patent/ATE529744T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT03808431T 2002-12-03 2003-12-03 Prionproteinliganden und verfahren zu ihrer verwendung ATE529744T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43042302P 2002-12-03 2002-12-03
PCT/US2003/038343 WO2004050851A2 (en) 2002-12-03 2003-12-03 Prion protein ligands and methods of use

Publications (1)

Publication Number Publication Date
ATE529744T1 true ATE529744T1 (de) 2011-11-15

Family

ID=32469468

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03808431T ATE529744T1 (de) 2002-12-03 2003-12-03 Prionproteinliganden und verfahren zu ihrer verwendung

Country Status (14)

Country Link
US (3) US7863411B2 (de)
EP (4) EP1573323B1 (de)
JP (1) JP4485367B2 (de)
CN (3) CN102241741B (de)
AT (1) ATE529744T1 (de)
AU (2) AU2003302500B2 (de)
CA (2) CA2836951C (de)
DK (4) DK2317317T3 (de)
ES (4) ES2460641T3 (de)
IL (3) IL168904A (de)
MX (2) MXPA05005920A (de)
NZ (3) NZ572892A (de)
PT (4) PT1953551E (de)
WO (1) WO2004050851A2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1395833B1 (de) * 2001-05-31 2013-02-27 Adlyfe, Inc. Verfahren zum erkennen von inkorrekt gefalteten proteinen
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
CA2836951C (en) 2002-12-03 2017-01-10 North Carolina State University Prion protein ligands and methods of use
AU2004229535A1 (en) * 2003-04-14 2004-10-28 Pathogen Removal And Diagnostic Technologies, Inc. Method for identifying ligands specific for structural isoforms of proteins
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
NZ580256A (en) 2003-08-13 2011-07-29 Novartis Vaccines & Diagnostic Prion-specific peptide reagents comprising the sequence KKRPKPGG
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
AU2006214463B2 (en) * 2005-02-15 2012-08-30 Presympto, Inc. Method for detecting misfolded proteins and prions
EP1931695B1 (de) * 2005-09-09 2013-04-10 Novartis AG Prionspezifische Peptoidreagentien
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
WO2008005960A2 (en) * 2006-07-07 2008-01-10 Pall Corporation Prion processing
EP2156181B1 (de) * 2006-07-28 2015-11-04 Adlyfe, Inc. Peptidsonden für diagnostik und therapie
CA2675039A1 (en) * 2007-01-12 2008-07-17 Alicon Ag Method for removing prion protein
BRPI0910550A2 (pt) * 2008-04-30 2015-09-29 Novartis Ag ensaio para confôrmeros patogênicos
CN102460167B (zh) 2009-04-15 2015-07-22 阿布拉科斯生物科学有限公司 不含朊病毒的纳米颗粒组合物和方法
JP5862560B2 (ja) * 2009-05-21 2016-02-16 アメリカン ナショナル レッド クロス レセプター随伴タンパク質（ｒａｐ）、前記の誘導体、模倣体および合成ペプチドによるプリオン増殖の阻害
US8841429B2 (en) * 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
JP2013510297A (ja) * 2009-11-04 2013-03-21 ノバルティス アーゲー モノマーからのタンパク質凝集体の分離における結合試薬としての正に荷電した種
US9162223B2 (en) 2011-12-21 2015-10-20 North Carolina State University Alkaline-stable chromatographic resins
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
CN103336124B (zh) * 2012-12-11 2015-07-15 武汉工业学院 一种检测朊病毒蛋白(PrPSC)的方法和试剂盒
EP2995621A1 (de) 2014-09-10 2016-03-16 Previpharma AG Liganden und Verfahren zur Isolierung oder Beseitigung von Proteinen
RU2018107453A (ru) 2015-08-10 2019-09-12 Эссенликс Корп. Устройства для анализов и способы в биологии/химии, предусматривающие упрощенные стадии, образцы небольшого объема, повышенную скорость и простоту применения
KR101982330B1 (ko) 2015-09-14 2019-05-24 에센릭스 코프. 증기 응축액 특히 입김 응축액을 수집 및 분석하기 위한 장치 및 시스템 그리고 이 장치 및 시스템을 사용하는 방법
MY194887A (en) 2015-09-14 2022-12-21 Essenlix Corp Device and System for Analyzing a Sample, Particularly Blood, as Well as Methods of Using The Same
CA3048002A1 (en) 2016-12-21 2018-06-28 Essenlix Corporation Devices and methods for authenticating a sample and use of the same
JP7003158B2 (ja) 2017-02-07 2022-01-20 エッセンリックス コーポレーション 圧縮開放流アッセイおよび使用
US11927560B2 (en) 2017-02-08 2024-03-12 Essenlix Corporation Bio/chemical material extraction and assay
CA3052809A1 (en) 2017-02-08 2018-08-23 Essenlix Corporation Qmax assays and applications
CA3053005A1 (en) 2017-02-08 2018-08-16 Essenlix Corporation Sample collection and handling for delayed analysis
WO2018148764A1 (en) 2017-02-08 2018-08-16 Essenlix Corporation Molecular manipulation and assay with controlled temperature
CN120685901A (zh) 2017-02-08 2025-09-23 上海宜晟生物科技有限公司 数字测定
CN110998325B (zh) 2017-02-09 2024-08-16 上海宜晟生物科技有限公司 扩增测定
WO2018148607A1 (en) 2017-02-09 2018-08-16 Essenlix Corporation Assay using different spacing heights
CN110770572B (zh) 2017-02-09 2023-08-18 Essenlix公司 比色测定
CA3053295A1 (en) 2017-02-15 2018-08-23 Essenlix Corporation Assay with rapid temperature change
JP7107953B2 (ja) 2017-02-16 2022-07-27 エッセンリックス コーポレーション テクスチャ表面を用いたアッセイ
EP3406632A1 (de) 2017-05-23 2018-11-28 S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati An prionprotein bindende liganden zur verwendung bei der behandlung von synukleinopathien
WO2018231877A1 (en) 2017-06-12 2018-12-20 Essenlix Corporation Homogeneous assay
WO2019028133A1 (en) 2017-08-01 2019-02-07 Essenlix Corporation DEVICES AND METHODS FOR EXAMINING THE EFFECTS OF MEDICINE ON MICROORGANISMS
US11280706B2 (en) 2017-08-01 2022-03-22 Essenlix Corporation Dilution calibration
US11243201B2 (en) 2017-08-01 2022-02-08 Essenlix Corporation Sample collection, holding and assaying
US12403465B2 (en) 2017-10-11 2025-09-02 Essenlix Corporation Containing a liquid sample
US11393561B2 (en) 2017-10-13 2022-07-19 Essenlix Corporation Devices and methods for authenticating a medical test and use of the same
US10807095B2 (en) 2017-10-26 2020-10-20 Essenlix Corporation Making and tracking assay card
US11237113B2 (en) 2017-10-26 2022-02-01 Essenlix Corporation Rapid pH measurement
US11609224B2 (en) 2017-10-26 2023-03-21 Essenlix Corporation Devices and methods for white blood cell analyses
US11648551B2 (en) 2017-12-12 2023-05-16 Essenlix Corporation Sample manipulation and assay with rapid temperature change
US11510608B2 (en) 2017-12-14 2022-11-29 Essenlix Corporation Devices, systems, and methods for monitoring hair
US11156606B2 (en) 2018-01-11 2021-10-26 Essenlix Corporation Homogeneous assay (II)
US11885952B2 (en) 2018-07-30 2024-01-30 Essenlix Corporation Optics, device, and system for assaying and imaging
JP7376040B2 (ja) * 2019-09-03 2023-11-08 国立大学法人京都工芸繊維大学 神経変性疾患におけるバイオマーカー分子の検出方法
CN115838395A (zh) * 2022-11-15 2023-03-24 西北农林科技大学 具有可溶性环氧化物水解酶抑制作用的活性肽及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601398A1 (de) * 1986-01-18 1987-07-23 Fresenius Ag Verwendung von oligopeptiden zur behandlung von cerebralen stoerungen
US5133866A (en) * 1988-03-24 1992-07-28 Terrapin Technologies, Inc. Method to identify analyte-bending ligands
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
DE68905387T2 (de) * 1988-06-22 1993-10-21 Ajinomoto Kk Aminosäure-Nahrungsmittelzusammensetzungen.
AU6753390A (en) * 1989-10-02 1991-04-28 University Of Michigan, The Bioanalytical detection system
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
HUT62312A (en) 1990-03-05 1993-04-28 Cephalon Inc Process for producing chymotrypsin-like proteases and their inhibitors
US5416013A (en) * 1990-04-04 1995-05-16 Sterling Winthrop Inc. Interleukin 1β protease and interleukin 1β protease inhibitors
US6995141B1 (en) * 1990-04-04 2006-02-07 Vertex Pharmaceuticals Incorporated Interleukin 1β protease and interleukin 1β protease inhibitors
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
GB9024005D0 (en) * 1990-11-05 1990-12-19 British Bio Technology Process for amplifying nucleic acid
NZ246059A (en) * 1991-12-03 1995-08-28 Proteus Molecular Design Synthetic polypeptides with at least one antigenic site of a prion protein, methods of their use and manufacture, antibodies thereto, compositions and kits
US5312730A (en) * 1992-05-27 1994-05-17 Ciba Corning Diagnostics Corp. Immune complex transfer with lypophilic bridge
CA2109646C (en) * 1992-11-24 2000-03-07 Gaston O. Daumy Para-nitroanilide peptides
JPH08178926A (ja) * 1994-10-25 1996-07-12 Sumitomo Pharmaceut Co Ltd イムノアッセイプレートおよびその用途
US5834318A (en) * 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
WO1997012992A2 (en) * 1995-10-02 1997-04-10 Royal Netherlands Academy Of Arts And Sciences Diagnosis method for a disease caused by a frameshift mutation in a gene and reagents therefore
US5750361A (en) 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
ATE249046T1 (de) * 1996-05-14 2003-09-15 Winnacker Ernst Ludwig Prof Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können
DE69714451T2 (de) * 1996-05-29 2003-01-30 Mcgill University, Montreal Prionbindende proteine und deren verwendungen
US5808011A (en) 1996-07-01 1998-09-15 Biopure Corporation Method for chromatographic removal of prions
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
JPH10182695A (ja) * 1996-12-27 1998-07-07 Teikoku Seiyaku Co Ltd ｇｐ１２０に対して親和性を有するペプチド
US6221614B1 (en) * 1997-02-21 2001-04-24 The Regents Of The University Of California Removal of prions from blood, plasma and other liquids
GB9710582D0 (en) * 1997-05-22 1997-07-16 Oxford Glycosciences Uk Ltd A method for de novo peptide sequence determination
US6211149B1 (en) * 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
US6750025B1 (en) * 1998-07-09 2004-06-15 V.I. Technologies, Inc. Method of detecting and isolating prion protein and variants thereof
DE19917838A1 (de) * 1999-01-12 2000-07-13 Bundesrepublik Deutschland Let Arzneimittel zur prophylaktischen oder therapeutischen Behandlung von transmissiblen spongiformen Enzephalopathien, Morbus Alzheimer und Corea Huntington und anderen neurodegenerativen Erkrankungen sowie diagnostische Mittel
AU6424300A (en) * 1999-05-27 2000-12-18 Max-Delbruck-Centrum Fur Molekulare Medizin Vaccines against conformation-dependent antigens and against antigens that are not or are not only proteins or peptides
MXPA01013186A (es) * 1999-06-23 2002-08-12 Caprion Pharmaceuticals Inc Peptidos de la proteina prion y sus usos.
AU5778400A (en) * 1999-06-29 2001-01-31 Caprion Pharmaceuticals, Inc. Prion protein binding proteins and uses thereof
US6261790B1 (en) * 1999-07-15 2001-07-17 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies and antibody cocktail for detection of prion protein as an indication of transmissible spongiform encephalopathies
WO2001006989A2 (en) * 1999-07-27 2001-02-01 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
WO2001019867A1 (de) * 1999-09-14 2001-03-22 Memorec Stoffel Gmbh Prionen-verwandtes protein
US6437102B1 (en) * 1999-11-24 2002-08-20 Bayer Corporation Method of separating prions from biological materials
AU2001245945A1 (en) * 2000-03-23 2001-10-03 Pe Corporation (Ny) Detection kits, such as nucleic acid arrays, for detecting the expression of 10,000 or more drosophila genes and uses thereof
AU2001251358A1 (en) * 2000-04-05 2001-10-23 V.I. Technologies, Inc. Prion-binding ligands and methods of using same
WO2001078344A1 (en) * 2000-04-12 2001-10-18 Sony Corporation Data transmission method and data transmission apparatus
GB0009918D0 (en) * 2000-04-20 2000-06-07 Rose Keith Covalent capture facilitating purification of polypeptides
US20020155106A1 (en) * 2000-12-01 2002-10-24 Hammond David J. Method of identifying a ligand for a target molecule
AU2002322887A1 (en) 2001-08-13 2003-03-03 Douglas A. Campbell Peptide sequence tags and method of using same
DE10152677A1 (de) * 2001-10-19 2003-05-08 Aventis Behring Gmbh Antikörper zum spezifischen Nachweis von pathogenen Prionen humanen Ursprungs und damit durchgeführten Nachweisverfahren
JP2003149461A (ja) * 2001-11-12 2003-05-21 Allied Tereshisu Kk 収納装置
CA2836951C (en) * 2002-12-03 2017-01-10 North Carolina State University Prion protein ligands and methods of use
US7510848B2 (en) * 2003-04-04 2009-03-31 North Carolina State University Prion protein binding materials and methods of use
NZ543371A (en) * 2003-04-04 2008-04-30 Pathogen Removal And Diagnosti Prion protein binding materials and methods of use
WO2006102099A2 (en) 2005-03-18 2006-09-28 The Regents Of The University Of California ANTIBODIES SPECIFIC FOR HUMAN AND BOVINE PrP

Also Published As

Publication number Publication date
US8604161B2 (en) 2013-12-10
WO2004050851A3 (en) 2005-01-27
ES2531926T3 (es) 2015-03-20
CN102241741A (zh) 2011-11-16
AU2010201499B2 (en) 2013-02-07
IL200468A (en) 2012-06-28
US9678085B2 (en) 2017-06-13
HK1124388A1 (en) 2009-07-10
CA2507936A1 (en) 2004-06-17
US20080268474A1 (en) 2008-10-30
IL168904A (en) 2010-11-30
NZ560410A (en) 2008-12-24
IL200468A0 (en) 2011-07-31
CN1739029B (zh) 2011-06-22
CN102297798B (zh) 2015-11-18
CN1739029A (zh) 2006-02-22
CA2836951A1 (en) 2004-06-17
EP1953551A2 (de) 2008-08-06
EP2312318B1 (de) 2014-10-08
HK1088948A1 (zh) 2006-11-17
JP2006509013A (ja) 2006-03-16
WO2004050851A2 (en) 2004-06-17
IL206129A0 (en) 2010-11-30
CN102241741B (zh) 2013-11-13
NZ572892A (en) 2010-03-26
HK1157010A1 (en) 2012-06-22
MXPA05005920A (es) 2006-03-17
CA2507936C (en) 2014-02-25
DK2317317T3 (en) 2015-03-02
CA2836951C (en) 2017-01-10
DK1573323T3 (da) 2012-01-23
PT2312318E (pt) 2015-01-14
MX337569B (es) 2016-03-09
EP1573323B1 (de) 2011-10-19
IL206129A (en) 2013-11-28
AU2003302500B2 (en) 2010-04-29
JP4485367B2 (ja) 2010-06-23
EP2312318A1 (de) 2011-04-20
CN102297798A (zh) 2011-12-28
US7863411B2 (en) 2011-01-04
ES2460641T3 (es) 2014-05-14
NZ540417A (en) 2008-04-30
PT1573323E (pt) 2012-01-10
ES2375958T3 (es) 2012-03-07
ES2527408T3 (es) 2015-01-23
AU2010201499A1 (en) 2010-05-06
AU2003302500A1 (en) 2004-06-23
EP1953551B1 (de) 2014-02-19
EP1953551A3 (de) 2009-03-18
EP1573323A2 (de) 2005-09-14
US20040229280A1 (en) 2004-11-18
EP1573323A4 (de) 2007-04-04
HK1157009A1 (en) 2012-06-22
EP2317317B1 (de) 2014-11-26
PT2317317E (pt) 2015-03-02
DK1953551T3 (da) 2014-05-12
DK2312318T3 (en) 2015-01-12
EP2317317A1 (de) 2011-05-04
PT1953551E (pt) 2014-05-06
US20140206021A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
IL200468A0 (en) Prion protein ligands and methods of use
DK1615992T3 (da) Prionproteinbindende materialer og fremgangsmåder til anvendelse
TNSN07136A1 (en) Prion protein binding materials and methods of use
DE60230927D1 (de) Fangverbindungen, ihre entnahme und verfahren zur analysierung des proteoms und von komplexen zusammensetzungen
DE69723860D1 (de) VERFAHREN ZUR BESTIMMUNG VON IgE
ATE491042T1 (de) Vorrichtung und verfahren zur quantifizierung von mrna aus vollblut mit hohem durchsatz
EP0957365A4 (de) Fluoreszierende polarisation
ATE426167T1 (de) Auto-antikírper gegen annexin-proteine als marker fur lungenkrebs
DE602004003842D1 (de) Verfahren und automatisiertes Microfluidsystem zum Nachweis von Proteinen in biologischen Proben
DE60326012D1 (de) Verfahren zur Konzentration von Proteinen
MY147996A (en) Sequential protein isolation and purification schemes by affinity chromatography.
DE60328055D1 (de) Verfahren zum nachweis von pathogenen mykobakterien in klinischen proben
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
ATE525462T1 (de) Proteomanalyseverfahren für phosphoryliertes protein
ATE392621T1 (de) Verfahren zur quantifizierung von glykiertem protein
DE602006013143D1 (de) Verfahren zum nachweis aggregatbildender zirkulierender proteinformen und mittel zum einfangen gebildeter aggregate
DE50212790D1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
DE602004011228D1 (de) Verfahren und zusammensetzungen zur bestimmung glycierter proteine
ATE441487T1 (de) System und verfahren zum inspizieren und sortieren von geformten behältern
EP1789592A4 (de) Verfahren zur identifizierung und quantifizierung von kurzen oder kleinen rna-molekülen
ATE533055T1 (de) Verfahren zum screenen mithilfe von konformationsempfindlichen peptiden
WO2006056438A3 (de) Protein-biochip zur validierung von bindern
ATE487791T1 (de) Verfahren und formulierung zur extraktion von nukleinsäuren aus beliebigen komplexen ausgangsmaterialien
ATE547161T1 (de) Verfahren zur quantitativen bestimmung von poloxameren
DE602004029589D1 (de) Testverfahren zur bestimmung von analyten mittels analytanalogen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1573323

Country of ref document: EP